SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending due to mixed market reactions following its Q4 earnings beat, as the stock experiences a significant dip despite exceeding revenue and EPS estimates. Community discussion centers on concerns over decelerating subscriber growth and conservative 2026 guidance, alongside the ongoing drama and shareholder sentiment surrounding the proposed Warner Bros. acquisition and its impact on buybacks and future debt.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is a trending topic as anticipation grows for its potential PMDA approval in Japan and its presentation at the J.P. Morgan Healthcare Conference, driving significant community discussion. Investors are actively highlighting the company's innovative Alpha DaRT technology and recent strong clinical data in pancreatic cancer, signaling a potential shift towards increased institutional interest in this transformative oncology player.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending as escalating geopolitical tensions, particularly surrounding potential US tariffs on European countries over Greenland, drive a significant 'risk-off' rotation in the markets. The community is actively discussing gold as a premier safe-haven asset, anticipating continued strong upside as investors seek protection against market instability and potential fiat currency debasement. This robust demand is pushing the metal to new highs amidst broader concerns over the US dollar and global economic conditions.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to recent reports of exceptionally high-grade silver drill results from its Nevada project and a broader surge in precious metals prices. The community is actively discussing continued accumulation by billionaire investor Eric Sprott and the potential for a significant short squeeze, while also noting recent commentary from CEO Diane Garrett regarding the company's capital position. Despite enthusiasm for its vast resources, some caution against its current lack of commercial production amid a rapidly rising valuation.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Holdings Inc

Ondas Holdings is trending following an investor day that revealed significantly raised revenue guidance and prompted numerous analyst price target upgrades, signaling strong confidence in its future trajectory. The community is actively discussing the company's robust position in autonomous systems, anticipating a substantial run fueled by potential defense contracts and strategic acquisitions. Despite broader market volatility, investors view recent dips as buying opportunities, reinforcing the long-term growth outlook in critical defense and communication infrastructure.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending due to recent significant government contract wins, notably with the U.S. Department of Health and Human Services and the U.S. Army, signaling increasing adoption of its enterprise AI solutions within the public sector. The community is actively debating whether these new contracts, combined with its high short interest and new leadership, position the company for a major turnaround despite past financial concerns and ongoing skepticism about its long-term growth trajectory.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is experiencing extreme volatility as natural gas prices surge dramatically, driven by recent colder weather forecasts and a significant short squeeze in the underlying commodity. This has led to a substantial decline in KOLD, with traders actively debating buying the dip amidst widespread discussion of the natural gas market's 'widowmaker' reputation. The community remains focused on weather pattern shifts and the sustainability of this rapid price movement, highlighting the inherent high risk of leveraged natural gas ETFs.

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Anteris Technologies Global Corp.

Anteris Technologies Global

Anteris Technologies (AVR) is currently trending following a significant strategic investment of up to $90 million from Medtronic and a concurrent public offering, which has sparked varied community reactions. While the Medtronic backing is widely viewed as a strong industry endorsement for its innovative DurAVR technology and potential for serious growth, concerns about substantial share dilution from the offering are also actively debated among investors. This comes as the company advances its global pivotal trial for the DurAVR heart valve, targeting the multi-billion-dollar TAVR market.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending following positive Phase 1 clinical trial data for its eczema drug, soquelitinib, which showed significant efficacy and safety, particularly in treatment-resistant patients. This promising development has fueled speculation about its blockbuster potential and future partnerships, even as the company's recent public offering sparks debate among investors regarding potential dilution versus funding for accelerated pipeline progression. The community is actively discussing the drug's strong profile and the ongoing battle between bulls and bears as the stock experiences substantial volatility.

TE Connectivity Plc is a company that engages in the provision of connectivity and sensor solutions for the purpose of distribution of power, signal, and data. It operates under the following segments: Transportation Solutions, Industrial Solutions, and Communications Solutions. The Transportation Solutions segment include terminals and connector systems and components, sensors, relays, antennas, and application tooling. The Industrial Solutions segment include terminals and connector systems and components, interventional medical components, relays, heat shrink tubing, and wire and cable. The Communications Solutions segment include terminals and connector systems and components, antennas, and heat shrink tubing. The company was founded in 2007 and is headquartered in Galway, Ireland.

TE Connectivity plc - Registered Shares

TE Connectivity Ltd - Registered Shares

TE Connectivity is trending following its robust fiscal Q1 earnings, which significantly exceeded expectations for both revenue and EPS, coupled with an optimistic outlook for the coming quarter. The community is highlighting the company's record orders and strong execution in high-growth areas like AI, next-gen vehicles, and energy infrastructure, leading to a largely bullish sentiment among analysts and investors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Adam Levy Acquires 8,832 Shares of Acrivon Therapeutics (NASDAQ:ACRV) Stock

Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) CFO Adam Levy bought 8,832 shares of the company's stock in a transaction on Wednesday, January 14th. The shares were acquired at an average...

Acrivon Therapeutics (NASDAQ:ACRV) CFO Adam Levy Acquires 8,832 Shares

Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) CFO Adam Levy bought 8,832 shares of the firm's stock in a transaction on Wednesday, January 14th. The stock was bought at an average price...

Acrivon Therapeutics (NASDAQ:ACRV) CEO Peter Blume-Jensen Purchases 49,000 Shares

Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) CEO Peter Blume-Jensen purchased 49,000 shares of the company's stock in a transaction that occurred on Wednesday, January 14th. The shares...

Acrivon Therapeutics (NASDAQ:ACRV) COO Eric Devroe Purchases 10,000 Shares

Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) COO Eric Devroe acquired 10,000 shares of the business's stock in a transaction that occurred on Tuesday, January 13th. The shares were...

Acrivon Therapeutics (NASDAQ:ACRV) COO Purchases $17,200.00 in Stock

Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) COO Eric Devroe bought 10,000 shares of the business's stock in a transaction that occurred on Tuesday, January 13th. The shares were...

Acrivon Stock Sinks 29% Despite Positive Phase 2b Endometrial Cancer Data

(RTTNews) - Acrivon Therapeutics, Inc. (ACRV) shares fell 28.71%, trading at $2.1044, down $0.8456, after the company reported updated Phase 2b clinical results for its lead candidate ACR-368 in...

Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls

Acrivon Therapeutics shares new trial data showing strong cancer responses, early tumor shrinkage, and pipeline progress, while confirming cash runway into 2027.read more...

Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan

Acrivon Therapeutics (NASDAQ:ACRV) highlighted new interim clinical results for its lead program ACR368 in endometrial cancer and provided early clinical and preclinical updates across its pipeline...

Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year?

Here is how Humacyte, Inc. (HUMA) and Acrivon Therapeutics, Inc. (ACRV) have performed compared to their sector so far this year.

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Rating of "Moderate Buy" from Analysts

Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seven analysts that are presently covering the stock, MarketBeat.com...

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.

Acrivon Therapeutics Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

ACRV
ACRIVON THERAPEUTICS INC

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ACRV News

ACRVACRIVON THERAPEUTICS INC